



Day-Storms, LLC

MEDICAL WRITING & RESEARCH

ACCURATE, EVIDENCE-BASED, AND TIMELY MEDICAL
CONTENT

GUIDELINES THIS WEEK...

National Cancer Comprehensive
Network (NCCN)

ERN GENTURIS -- Birt-Hogg-Dubé
syndrome

ERN -- Bardet-Biedl syndrome

Weekly Guideline Update

Each Wednesday, I bring you news concerning updates to guidelines and recommendations by professional societies. This list is not all-inclusive, of course, but the following recent updates caught my attention.

If there are any guidelines I have missed this week that you would like to see included, please email me at jerm@day-storms.com.

National Cancer Comprehensive Network (NCCN)

The NCCN guidelines can be found at www.nccn.org.

- Ampullary Adenocarcinoma Version 2.2024 – The NCCN has added repotrectinib as a possible first-line therapy for metastatic disease for patients with *NTRK* gene fusion-positive tumors.
- Gastrointestinal Stromal Tumors Version 2.2024 – Similarly, repotrectinib was added as a first- and second-line therapy for *NTRK* gene fusion-positive tumors as well as a possible neoadjuvant therapy for resectable disease.

- Neuroendocrine and Adrenal Tumors Version 2.2024 – For patients with *NTRK* gene fusion-positive tumors with locoregional unresectable or metastatic disease, repotrectinib may be considered if tumors progressed on a prior *NTRK*-targeted therapy.
- Occult Primary (Cancer of Unknown Primary [CUP]) Version 1.2025 – Within the new occult primary guidelines, the NCCN has added skin and/or oral cavity to the history and physical exam of the initial evaluation. The NCCN has also replaced the wording regarding the recommendation against gene sequencing to determine tissue of origin with broader terminology (ie, “tissue of origin studies”). Endoscopy as indicated has been added to the additional workup for supraclavicular nodes. Regarding immunohistochemistry (IHC) and in situ hybridization (ISH), the NCCN recommends selecting a focused panel of IHC or ISH markers rather than testing for a large series of markers. Finally, repotrectinib has also been added as a potential therapy for *NTRK* gene fusion-positive tumors.
- Pancreatic Adenocarcinoma Version 3.2024 – The guidelines introduce repotrectinib as a new treatment option for patients with *NTRK* gene fusion-positive tumors across various disease stages and performance statuses. The discussion section has also been modified to reflect algorithm changes.
- Soft Tissue Sarcoma Version 2.2024 – As with many other NCCN guidelines, the soft tissue sarcoma guidelines have been updated to include repotrectinib as a treatment option for *NTRK* gene fusion-positive tumors based on the TRIDENT-1 clinical trial.

European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS)

The [ERN GENTURIS guidelines](#) for Birt-Hogg-Dubé syndrome (BHD) emphasize a multidisciplinary approach to diagnosis, surveillance, and management. BHD, caused by pathogenic variants in the *FLCN* gene, manifests with benign skin lesions, pulmonary cysts, and a predisposition to renal cell carcinoma (RCC). Diagnosis should consider genetic testing in patients with relevant clinical features, including spontaneous pneumothorax, bilateral pulmonary cysts, and renal neoplasia. Lifelong renal surveillance, starting at age 20 with MRI or ultrasound, is recommended due to the risk of RCC. Treatment guidelines focus on nephron-sparing techniques for renal tumors, while cutaneous and pulmonary manifestations require tailored interventions based on individual patient needs.

European Reference Network

The [ERN guidelines](#) for Bardet-Biedl syndrome (BBS) focus on comprehensive, multidisciplinary care. BBS is characterized by primary features like retinal degeneration, obesity, polydactyly, renal anomalies, and cognitive impairment. Early genetic diagnosis is crucial. Surveillance includes regular ophthalmic, renal, and metabolic evaluations. Management emphasizes lifestyle modifications, early intervention for obesity and its complications, and nephron-sparing strategies for renal disease. Genetic counseling and tailored supportive therapies, including visual aids and psychosocial support, are integral to improving patient outcomes.